Thermedical is a pioneering medical technology company specializing in thermal ablation therapy using Saline Enhanced Radiofrequency (SERF) energy. The company's core product, the Thermedical Ablation System, is designed to create durable, transmural lesions that can prevent the recurrence of ventricular tachycardia (VT) and treat other soft tissue conditions. The system is 510k cleared for the coagulation and ablation of soft tissue during percutaneous, laparoscopic, and intraoperative surgical procedures. However, its use for treating VT is currently investigational and not approved for sale in any market.

Thermedical primarily serves healthcare providers, including hospitals and specialized cardiac treatment centers. Operating in the medical device market, the company aims to offer a safer, more effective alternative to existing ablation technologies. The business model revolves around the sale and distribution of its ablation system and related consumables, generating revenue through direct sales and partnerships with healthcare institutions.

The company has received FDA and Health Canada approval for its degassed saline solution and has earned FDA Breakthrough Device Designation, highlighting its innovative approach to medical treatment. By focusing on treating the underlying disease rather than just the symptoms, Thermedical aims to improve patient outcomes and procedural safety.

Keywords: thermal ablation, ventricular tachycardia, SERF energy, medical technology, FDA approval, healthcare providers, cardiac treatment, soft tissue ablation, investigational device, innovative therapy.